Mounjaro vs Wegovy: Which Weight Loss Injection Is Right for You?

When exploring prescription medical weight management in the UK, two weekly injectable medications lead the field: Mounjaro (tirzepatide) and Wegovy (semaglutide). While both belong to the incretin-mimetic family and work by regulating appetite and fullness, their underlying molecular mechanisms, dosage ladders, and clinical trial results differ significantly.

Selecting the right medication depends on your target weight reduction goals, tolerability during dose escalation, health history, and private prescription preferences.

You can discreetly complete a digital consultation and explore weight management treatments through the WellAssist Pharmacy Hub.

The Atomic Answer: The Science in 60 Seconds

Wegovy (semaglutide) is a single-receptor GLP-1 agonist that mimics the body’s natural satiety hormone to reduce appetite and delay stomach emptying. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist that targets two distinct metabolic pathways, delivering higher average weight loss in head-to-head clinical trials (roughly 20% vs 15% body weight reduction at standard maintenance doses). Both require a once-weekly self-injection alongside dietary and lifestyle changes.

Head-to-Head Comparison: Mounjaro vs. Wegovy

Feature	Mounjaro (Tirzepatide)	Wegovy (Semaglutide)
Mechanism	Dual GIP + GLP-1 receptor agonist	Single GLP-1 receptor agonist
Frequency	Once weekly (subcutaneous injection)	Once weekly (subcutaneous injection)
Average Weight Loss	~20% to 22.5% of total body weight	~15% to 17% (up to ~20% at maximum 7.2mg dose)
Dosing Ladder	2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg	0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg (up to 7.2mg)
Cardiovascular Benefit	Proven blood pressure and metabolic improvements	FDA/MHRA approved for reducing cardiovascular risk
Common Side Effects	Nausea, constipation, diarrhoea, mild indigestion	Nausea, vomiting, constipation, headache
UK Availability	Explore Mounjaro Options	Explore Wegovy Options

Key Factors to Consider Before Choosing

                   ┌─────────────────────────────────────────┐
                   │  Primary Clinical Goal & History Check  │
                   └────────────────────┬────────────────────┘
                                        │
             ┌──────────────────────────┴──────────────────────────┐
             ▼                                                     ▼
┌─────────────────────────┐                           ┌─────────────────────────┐
│ Maximum Average Weight  │                           │ Proven Cardiovascular   │
│ Loss (Dual Pathway)     │                           │ Risk Reduction          │
└────────────┬────────────┘                           └────────────┬────────────┘
             │                                                     │
             ▼                                                     ▼
┌─────────────────────────┐                           ┌─────────────────────────┐
│   Choose MOUNJARO       │                           │     Choose WEGOVY       │
│ (Tirzepatide 2.5–15mg)  │                           │ (Semaglutide 0.25–2.4mg)│
└─────────────────────────┘                           └─────────────────────────┘

1. Single vs. Dual Hormone Action

• Wegovy targets GLP-1 receptors in the brain and gut, signaling to your brain that you are full and slowing down stomach emptying.
• Mounjaro targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. By combining these pathways, Mounjaro enhances insulin sensitivity and fat metabolism, leading to greater average weight loss in clinical trials (such as SURMOUNT-5).

2. Dosage Escalation & Flexibility

Both medications require step-by-step titration every 4 weeks to allow your gastrointestinal system to adapt and minimize side effects:

• Wegovy escalates from 0.25mg up to a standard 2.4mg maintenance dose (with high-dose options available for selected non-responders).
• Mounjaro offers more titration tiers (2.5mg up to 15mg), allowing your prescribing clinician to fine-tune your dose if you experience plateaus or side effects.

3. Side Effect Profiles

Because both drugs delay gastric emptying, nausea, heartburn, constipation, and diarrhoea are the most common initial symptoms. Clinical trials note slightly lower treatment discontinuation rates due to side effects with Mounjaro, but individual tolerance varies widely.

3 Rules for Safe Weight Loss Medication Usage

1. Follow the Titration Schedule: Never skip dose levels to accelerate weight loss. Rushing through titration drastically increases the risk of severe nausea, vomiting, or dehydration.
2. Prioritise Protein and Hydration: Reduced appetite can lead to muscle loss if protein intake drops too low. Drink 2–3 litres of water daily and focus on nutrient-dense meals.
3. Prescription Eligibility: In the UK, these treatments are prescription-only for individuals with a BMI of ≥30 (or ≥27 with weight-related health conditions like hypertension or dyslipidaemia).

Frequently Asked Questions